Combination Iron Chelation Therapy

Completed · Phase 1

Conditions studied: Iron Overload, Thalassemia

In brief

Patients with beta-thalassemia (Cooley's Anemia) continue to suffer from the transfusion-induced iron overload due to the inadequacies of current iron-chelation therapy. Compliance with the use of the only FDA-approved drug for removing excess iron from patients (Desferal) continues to be a major problem despite convincing evidence that it markedly reduces morbidity and prolongs life. The full potential of iron-chelation therapy will not be realized until an orally-effective drug is available. This small trial is testing the premise that a combination of drugs as a new approach to iron chelation therapy may reduce side effects and increase efficacy. If both drugs can be given orally, there may be a better chance of finding a suitable alternative to Desferal. Several combinations of experimental iron chelating drugs are being used in this trial.

Key facts

Study ID

NCT00004982

Run by

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Starts

1998-12-01

Expected to finish

2002-11-01

Last updated by the study team

2010-01-14

Who can join

Age: 7 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Iron overload

You may not qualify if…

• Overt cardiac disease

Where it is running

• Cornell University Medical College — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.